XML 50 R25.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | 14. Income Taxes The Company is subject to U.S. federal and various state corporate income taxes as well as taxes in foreign jurisdictions for the foreign parent and where foreign subsidiaries have been established. Net loss before taxes For the years ended December 31, 2024, 2023 and 2022, the net loss before income taxes consist of the following (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Domestic |  | $ | 41,232 |  |  | $ | 30,357 |  |  | $ | 1,321 |
Foreign |  |  | (403,897 | ) |  |  | (181,079 | ) |  |  | (651,821 | )
Total |  | $ | (362,665 | ) |  | $ | (150,722 | ) |  | $ | (650,500 | )
The (provision) benefit for income taxes consist of the following (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Current income taxes: |  |  |  |  |  |  |  |  |
Federal |  | $ | (2,592 | ) |  | $ | (2,318 | ) |  | $ | (444 | )
State |  |  | (1,479 | ) |  |  | (994 | ) |  |  | (241 | )
Foreign |  |  | — |  |  |  | — |  |  |  | — |
Total current income taxes |  |  | (4,071 | ) |  |  | (3,312 | ) |  |  | (685 | )
Deferred income taxes: |  |  |  |  |  |  |  |  |
Federal |  | $ | 492 |  |  |  | 424 |  |  |  | 1,010 |
State |  |  | (8 | ) |  |  | — |  |  |  | — |
Foreign |  |  | — |  |  |  | — |  |  |  | — |
Total deferred income taxes |  |  | 484 |  |  |  | 424 |  |  |  | 1,010 |
Total income tax (provision) benefit |  | $ | (3,587 | ) |  | $ | (2,888 | ) |  | $ | 325 |
A reconciliation of income tax expense computed at the statutory corporate income tax rate to the effective income tax rate for the years ended December 31, 2024, 2023 and 2022 is as follows:
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Income tax expense at statutory rate |  |  | 11.9 | % |  |  | 11.9 | % |  |  | 11.9 | %
State income tax, net of federal benefit |  |  | 1.1 | % |  |  | 2.3 | % |  |  | 1.2 | %
Nondeductible expenses |  |  | 0.0 | % |  |  | (0.2 | )% |  |  | (0.2 | )%
Foreign rate differential |  |  | (1.0 | )% |  |  | (2.1 | )% |  |  | (0.1 | %)
Statutory to U.S. GAAP permanent differences |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
Stock-based compensation |  |  | (0.4 | )% |  |  | (4.0 | %) |  |  | (0.2 | )%
Impact of deferred rate change |  |  | (0.1 | )% |  |  | 0.1 | % |  |  | (0.1 | )%
Research credits |  |  | 2.7 | % |  |  | 8.2 | % |  |  | 3.3 | %
Change in valuation allowance |  |  | (15.2 | )% |  |  | (17.2 | )% |  |  | (15.8 | )%
Other Rate Items |  |  | 0.0 | % |  |  | (0.9 | )% |  |  | 0.0 | %
Effective income tax rate |  |  | (1.0 | %) |  |  | (1.9 | %) |  |  | — |
The federal statutory rate reflects the Switzerland mixed company service rate. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |
Deferred tax assets: |  |  |  |  |  |
Net operating loss carryforwards |  | $ | 178,061 |  |  | $ | 133,384 |
Accruals and reserves |  |  | 4,479 |  |  |  | 4,485 |
Operating lease liabilities |  |  | 60,570 |  |  |  | 65,177 |
Other deferred tax assets |  |  | 17,809 |  |  |  | 15,987 |
Stock-based compensation |  |  | 20,553 |  |  |  | 18,346 |
Research credit |  |  | 74,012 |  |  |  | 70,404 |
Total deferred tax assets |  |  | 355,484 |  |  |  | 307,783 |
Less valuation allowance |  |  | (282,739 | ) |  |  | (227,615 | )
Net deferred tax assets |  |  | 72,745 |  |  |  | 80,168 |
Deferred tax liabilities: |  |  |  |  |  |
Depreciation |  |  | (34,078 | ) |  |  | (38,725 | )
Operating lease assets |  |  | (38,845 | ) |  |  | (42,058 | )
Intangible assets |  |  | — |  |  |  | (4 | )
Other deferred tax liabilities |  |  | (36 | ) |  |  | — |
Total deferred tax liabilities |  |  | (72,959 | ) |  |  | (80,787 | )
Long term deferred taxes |  | $ | (214 | ) |  | $ | (619 | )
The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of worldwide operating losses, the Company has concluded that it is more-likely-than-not that the benefit of its U.S. and non-U.S. deferred tax assets will not be realized. Accordingly, as of December 31, 2024 and 2023, the Company has provided a full valuation allowance against its net deferred tax assets in Switzerland and the United Kingdom. The Company has also provided a valuation allowance against the U.S. deferred tax assets that cannot be realized by existing deferred tax liabilities based upon when they are scheduled to reverse. The valuation allowance increased by $55.1 million during 2024, which is primarily attributable to increase in net operating loss carryforwards as a result of current year net loss. As of December 31, 2024, the Company had no available U.S. federal net operating loss carryforwards. As of December 31, 2024, the Company had available non-U.S. net operating loss carryforwards of $2,982.0 million of which $1,489.7 million relate to Switzerland, $1,489.7 million relate to the Canton of Zug, and $2.6 million relate to the Company’s wholly-owned subsidiary in the United Kingdom. The net operating losses generated in Switzerland and the Canton of Zug begin to expire in 2027 and the net operating losses generated in the United Kingdom can be carried forward indefinitely. As of December 31, 2024, the Company had U.S. domestic federal research and development credit carryforwards of $29.8 million that begin to expire in 2040 for federal purposes, which are net of uncertain tax positions of $22.3 million. As of December 31, 2024, the Company had U.S. domestic federal orphan drug credit carryforwards of $27.0 million which begin to expire in 2040 for federal purposes, which are net of uncertain tax positions of $11.5 million. As of December 31, 2024, the Company had U.S. domestic state research and development credit carryforwards of $21.8 million which begin to expire in 2035, which are net of uncertain tax positions of $14.5 million. ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statement by prescribing the minimum recognition threshold and measurement of a tax position taken or expected to be taken in a tax return. As of December 31, 2024, the Company had gross unrecognized tax benefits of $50.0 million of which $45.6 million would favorably impact the effective tax rate if recognized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, interest and penalties recognized in the Company's financial statements related to uncertain tax positions were not material. A s of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company’s consolidated statements of operations and comprehensive loss. The aggregate changes in gross unrecognized tax benefits were as follows (in thousands):
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Balance at beginning of year |  | $ | 44,148 |  |  | $ | 34,536 |  |  | $ | 21,395 |
Increases for tax positions taken during current period |  |  | 5,777 |  |  |  | 9,703 |  |  |  | 10,439 |
Increases for tax positions taken in prior periods |  |  | 34 |  |  |  | — |  |  |  | 2,702 |
Decreases for tax positions taken during current period |  |  | — |  |  |  | — |  |  |  | — |
Decreases for tax positions taken in prior periods |  |  | — |  |  |  | (91 | ) |  |  | — |
Balance at end of year |  | $ | 49,959 |  |  | $ | 44,148 |  |  | $ | 34,536 |
The Company files income tax returns in the U.S. federal jurisdiction, Massachusetts, California and certain non-U.S. jurisdictions. The Company is subject to U.S. federal, Massachusetts, California and non-U.S. income tax examinations by authorities for tax years ending after December 31, 2020. Research credits generated in prior tax years that are closed for examination may still be adjusted upon future examination if they have or will be used in a future period. The Company is subject to income tax examinations by authorities in its non-U.S. jurisdictions for all years.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration